(Q37367999)

20 August 2017

title

Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab (English)

1 reference

20 August 2017

0 references

ankylosing spondylitis

1 reference

1 reference

Valdeŕilio Feijó Azevedo

1

1 reference

20 August 2017

C Parchen

2

1 reference

20 August 2017

S A Coelho

3

1 reference

20 August 2017

D C Lacerda

4

1 reference

20 August 2017

C G Hirth

5

1 reference

20 August 2017

publication date

14 January 2009

1 reference

Rheumatology International

20 August 2017

published in

1 reference

20 August 2017

volume

29

1 reference

20 August 2017

issue

11

1 reference

20 August 2017

page(s)

1381-1384

1 reference

Tuberculous myositis: a rare but existing clinical entity

20 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00296-008-0837-8

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

12 December 2020

[Miliary tuberculosis following treatment with adalimumab]

1 reference

12 December 2020

Generalised skeletal muscle tuberculosis.

1 reference

12 December 2020

Adalimumab for the treatment of ankylosing spondylitis

1 reference

12 December 2020

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

12 December 2020

Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study

1 reference

12 December 2020

Soft tissue tuberculosis: a series of 11 cases.

1 reference

12 December 2020

Tuberculosis in patients treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?

1 reference

12 December 2020

Tuberculous pyomyositis: an unusual presentation of disseminated Mycobacterium tuberculosis infection

1 reference

12 December 2020

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment

1 reference

12 December 2020

Tuberculosis of the ribs: computed tomographic findings

1 reference

12 December 2020

Bone and joint tuberculosis: a continuing problem

1 reference

12 December 2020

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

12 December 2020

Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab.

1 reference

12 December 2020

Isolated tuberculous pyomyositis in a renal transplant patient

1 reference

12 December 2020

Tuberculous myositis: an unusual presentation of extrapulmonary tuberculosis

1 reference

12 December 2020

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

1 reference

12 December 2020

10.1007/S00296-008-0837-8

Identifiers

DOI

1 reference

20 August 2017

1 reference